Abstract
The nonapeptide bradykinin is an important growth factor for many cancers. Certain peptide and non-peptide bradykinin antagonists show remarkable anti-cancer activities in both in vitro and in vivo cancer models, especially of lung and prostate cancers. Bradykinin antagonists stimulate apoptosis in cancers by a novel “biased agonist” mechanism: they block intracellular increase of calcium concentration but stimulate the MAP kinase pathway. This unbalanced effect stimulates caspase activation. In nude mouse xenotransplants of lung and prostate cancers the antagonists inhibit angiogenesis and activation of membrane metalloproteases (MMP 2 and 9). In the xenotransplants certain bradykinin antagonists showed higher potency than standard anti-cancer drugs, without evident toxicity to the hosts. These compounds offer great promise for development of new anti-cancer drugs.
Keywords: Bradykinin, peptide, xenotransplants, antagonists, metalloproteases
Current Pharmaceutical Design
Title: Bradykinin Antagonists as Anti-Cancer Agents
Volume: 9 Issue: 25
Author(s): J. M. Stewart
Affiliation:
Keywords: Bradykinin, peptide, xenotransplants, antagonists, metalloproteases
Abstract: The nonapeptide bradykinin is an important growth factor for many cancers. Certain peptide and non-peptide bradykinin antagonists show remarkable anti-cancer activities in both in vitro and in vivo cancer models, especially of lung and prostate cancers. Bradykinin antagonists stimulate apoptosis in cancers by a novel “biased agonist” mechanism: they block intracellular increase of calcium concentration but stimulate the MAP kinase pathway. This unbalanced effect stimulates caspase activation. In nude mouse xenotransplants of lung and prostate cancers the antagonists inhibit angiogenesis and activation of membrane metalloproteases (MMP 2 and 9). In the xenotransplants certain bradykinin antagonists showed higher potency than standard anti-cancer drugs, without evident toxicity to the hosts. These compounds offer great promise for development of new anti-cancer drugs.
Export Options
About this article
Cite this article as:
Stewart M. J., Bradykinin Antagonists as Anti-Cancer Agents, Current Pharmaceutical Design 2003; 9 (25) . https://dx.doi.org/10.2174/1381612033454171
DOI https://dx.doi.org/10.2174/1381612033454171 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modulation of the Cell Cycle and Induction of Apoptosis in Human Cancer Cells by Synthetic Bile Acids
Current Cancer Drug Targets Human Reduced Folate Carrier Gene and Transcript Variants: Functional, Physiologic, and Pharmacologic Consequences
Current Pharmacogenomics A Review of Animal and Human Studies for Management of Benign Prostatic Hyperplasia with Natural Products: Perspective of New Pharmacological Agents
Inflammation & Allergy - Drug Targets (Discontinued) Radioligands for the Angiotensin II Subtype 1 (AT1) Receptor
Current Topics in Medicinal Chemistry Open Questions on Bioequivalence: An Updated Reappraisal
Current Clinical Pharmacology Meet Our Editorial Board Member
Recent Patents on Anti-Cancer Drug Discovery Advances in Human Cytochrome P450 and Personalized Medicine
Current Drug Metabolism Subject Index to Volume 4
Current Drug Targets Biomarker Discovery and Translation in Metabolomics
Current Metabolomics Lessons we Learned from High-Throughput and Top-Down Systems Biology Analyses about Glioma Stem Cells
Current Pharmaceutical Design New Features in the Treatment of Androgen-Independent Prostate Cancer
Current Pharmaceutical Design Antidepressant-Like Components of Hypericum perforatum Extracts: An Overview of Their Pharmacokinetics and Metabolism
Current Drug Metabolism Radioactive Gold Nanoparticle in Two Forms (<sup>198</sup><sub>79</sub>Au GNPs and <sup>99m</sup>Tc-GNPs) for Lung Cancer Antiproliferative Induction and Intralesional Imaging: A Proof of Concept
Anti-Cancer Agents in Medicinal Chemistry Docking and QSAR Studies of Aryl-valproic Acid Derivatives to Identify Antiproliferative Agents Targeting the HDAC8
Anti-Cancer Agents in Medicinal Chemistry The Mechanisms of Anticancer Agents by Genistein and Synthetic Derivatives of Isoflavone
Mini-Reviews in Medicinal Chemistry Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Current Signal Transduction Therapy PNP Anticancer Gene Therapy
Current Topics in Medicinal Chemistry Small Non-Coding RNAs as Biomarkers
Recent Patents on Biomarkers Antioxidant Effects of Natural Bioactive Compounds
Current Pharmaceutical Design Patents and the Development on Polymer based Nanomaterial (PAMAM Dendrimer) for Biomedical Applications
Recent Patents on Biomedical Engineering (Discontinued)